NCT03534453: L-MOCA

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Completed Phase 3 Last updated 10 July 2025

What this trial tests

Phase 3 trial testing Olaparib 300mg tablets in Relapsed Ovarian Cancer in 229 participants. Completed in 27 January 2025.

Timeline

29 May 2018

Primary endpoint
27 January 2025

27 January 2025

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	229
Start date	29 May 2018
Primary completion	27 January 2025
Estimated completion	27 January 2025
Sites	25 locations across China, Malaysia

Drugs / interventions tested

• Olaparib 300mg tablets — full drug profile →

Conditions studied

• Relapsed Ovarian Cancer — all drugs for Relapsed Ovarian Cancer →
• Following Complete or Partial Response to Platinum Based Chemotherapy — all drugs for Following Complete or Partial Response to Platinum Based Chemotherapy →
• Platinum Sensitive — all drugs for Platinum Sensitive →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, female only, with Relapsed Ovarian Cancer or Following Complete or Partial Response to Platinum Based Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
   Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
2. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
   Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
3. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
   Ledermann JA, Pujade-Lauraine E. · · 2019 · cited 68× · PMID 31205507 · DOI 10.1177/1758835919849753
4. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
   Gao Q, Zhu J, Zhao W, Huang Y, et al · · 2022 · cited 30× · PMID 35131903 · DOI 10.1158/1078-0432.ccr-21-3023
5. Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
   Montemorano L, Lightfoot MD, Bixel K. · · 2019 · cited 22× · PMID 31920338 · DOI 10.2147/ott.s195552
6. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer.
   Xiao F, Wang Z, Qiao L, Zhang X, et al · · 2024 · cited 18× · PMID 39169400 · DOI 10.1186/s12967-024-05583-z
7. Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
   Zheng J, Li Z, Min W. · · 2022 · cited 16× · PMID 36756144 · DOI 10.3389/fphar.2022.979873
8. Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review.
   Watanabe K, Seki N. · · 2024 · cited 14× · PMID 38255825 · DOI 10.3390/ijms25020752